	US 11,684,637 B2
	Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
Griffith Parks, Orlando, FL (US); and Alicja Copik, Casselberry, FL (US)
Assigned to UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., Orlando, FL (US)
Appl. No. 16/616,671
Filed by UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., Orlando, FL (US)
PCT Filed May 25, 2018, PCT No. PCT/US2018/034655 § 371(c)(1), (2) Date Nov. 25, 2019, PCT Pub. No. WO2018/218151, PCT Pub. Date Nov. 29, 2018.
Claims priority of provisional application 62/511,010, filed on May 25, 2017.
Prior Publication US 2021/0145876 A1, May 20, 2021
Int. Cl. A61K 35/76 (2015.01); A61K 35/768 (2015.01); C07K 14/705 (2006.01); C12N 7/00 (2006.01); A61K 35/17 (2015.01); C07K 16/00 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 35/768 (2013.01); C07K 14/705 (2013.01); C07K 16/00 (2013.01); C12N 7/00 (2013.01); C12N 2760/18721 (2013.01); C12N 2760/18732 (2013.01); C12N 2760/18745 (2013.01)]

27 Claims

1. An engineered oncolytic virus wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor, wherein the one or more exogenous membrane bound immune cell targeting ligands comprise an immunoglobulin Fc domain modified to have an inverted orientation with its amino terminal end facing intracellularly.